Fintel reports that on April 9, 2025, HC Wainwright & Co. downgraded their outlook for Rallybio (NasdaqGS:RLYB) from Buy to ...

Fintel reports that on April 9, 2025, HC Wainwright & Co. initiated coverage of vTv Therapeutics (NasdaqCM:VTVT) with a Buy ...

H.C. Wainwright raised the firm’s price target on FTC Solar (FTCI) to $5 from $1.50 and keeps a Buy rating on the shares following the 1-for-10 ...

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm’s price target on Genmab (GMAB) to $37 from $50 and keeps a Buy rating on the ...

Stock analysts at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Alnylam ...

H.C. Wainwright analyst Patrick Trucchio initiated coverage of Alto Neuroscience (ANRO) with a Buy rating and $10 price ...

Research analysts at HC Wainwright boosted their Q1 2025 earnings per share (EPS) estimates for Mineralys Therapeutics in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now ...

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

Fintel reports that on April 3, 2025, HC Wainwright & Co. initiated coverage of Kairos Pharma (NYSEAM:KAPA) with a Buy recommendation. As of April 2, 2025, the average one-year price target for ...

Fintel reports that on April 1, 2025, HC Wainwright & Co. initiated coverage of Rezolve AI (NasdaqGM:RZLV) with a Buy recommendation. As of March 19, 2025, the average one-year price target for ...

On Friday, H.C. Wainwright’s analysts reaffirmed a Buy rating on Altimmune (NASDAQ:ALT) shares, with a steady price target of $12.00. According to InvestingPro data, the stock is currently trading ...